Abstract
Albendazole, an anthelmintic drug belonging to BCS class II, has poor bioavailability. Bioavailability is dissolution rate dependent and hence needs novel approach for enhancement of bioavailability. The aim of the study was to develop nanosuspension of albendazole by using various techniques like nanoprecipitation, emulsion template and sonication. Nanosuspensions were prepared using polyvinylpyrrolidone K30 as a stabilizer and Tween 80 as a surfactant. Average particle size, zeta potential, particle size distribution, pH, viscosity, photomicrography, sedimentation, redispersibility and % drug content were determined to characterize prepared nanosuspensions. In vitro release study was performed in 0.1N HCl using cellophane membrane and compared with marketed product. Residual solvent determination was carried out by gas chromatography for nanosuspensions prepared by nanoprecipitation and emulsion template techniques. All the results obtained for characterization were satisfactory. The prepared nanosuspensions showed particle size 673±9.18 nm to 893±21.6 nm, zeta potential -8.70±0.5mV to -8.96±0.8, polydispersity index 0.204±0.04 to 0.644±0.07. In vitro release study of the nanosuspensions showed 33.80% to 42.92% drug release in first hour which was higher than the marketed suspension (16.19% release in first hour). The optimized nanosuspensions showed up to 97.05 % drug release within 6-8 hours while marketed product showed up to 91.03% drug release within 10 hours.
Keywords: Albendazole, bioavailability, dissolution, emulsion template, nanoprecipitation, sonication.
Drug Delivery Letters
Title:Development of Albendazole Nanosuspension by Various Techniques
Volume: 4 Issue: 2
Author(s): Akshay Koli, Himanshu Bhatt, Ashish Patel, Sandip Bhagat, Shailesh Shah and Ketan Ranch
Affiliation:
Keywords: Albendazole, bioavailability, dissolution, emulsion template, nanoprecipitation, sonication.
Abstract: Albendazole, an anthelmintic drug belonging to BCS class II, has poor bioavailability. Bioavailability is dissolution rate dependent and hence needs novel approach for enhancement of bioavailability. The aim of the study was to develop nanosuspension of albendazole by using various techniques like nanoprecipitation, emulsion template and sonication. Nanosuspensions were prepared using polyvinylpyrrolidone K30 as a stabilizer and Tween 80 as a surfactant. Average particle size, zeta potential, particle size distribution, pH, viscosity, photomicrography, sedimentation, redispersibility and % drug content were determined to characterize prepared nanosuspensions. In vitro release study was performed in 0.1N HCl using cellophane membrane and compared with marketed product. Residual solvent determination was carried out by gas chromatography for nanosuspensions prepared by nanoprecipitation and emulsion template techniques. All the results obtained for characterization were satisfactory. The prepared nanosuspensions showed particle size 673±9.18 nm to 893±21.6 nm, zeta potential -8.70±0.5mV to -8.96±0.8, polydispersity index 0.204±0.04 to 0.644±0.07. In vitro release study of the nanosuspensions showed 33.80% to 42.92% drug release in first hour which was higher than the marketed suspension (16.19% release in first hour). The optimized nanosuspensions showed up to 97.05 % drug release within 6-8 hours while marketed product showed up to 91.03% drug release within 10 hours.
Export Options
About this article
Cite this article as:
Koli Akshay, Bhatt Himanshu, Patel Ashish, Bhagat Sandip, Shah Shailesh and Ranch Ketan, Development of Albendazole Nanosuspension by Various Techniques, Drug Delivery Letters 2014; 4 (2) . https://dx.doi.org/10.2174/22103031113036660016
DOI https://dx.doi.org/10.2174/22103031113036660016 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Protective Role of Heme Oxygenase-1 in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Endothelial Regenerative Capacity and Aging: Influence of Diet, Exercise and Obesity
Current Cardiology Reviews Serum Uric Acid and Risk of Coronary Heart Disease
Current Pharmaceutical Design Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design Posterior Internal Frontal Artery Vascularization of the Precentral Gyrus Responsible for Proximal Arm Movement: Insight from a Case of Coil Migration
Current Neurovascular Research Research Advances on Anticancer Effect of Licorice
Current Bioactive Compounds Therapeutic Use of Calcitriol
Current Vascular Pharmacology High Mobility Group Box 1 Protein as a Potential Drug Target for Infection- and Injury-Elicited Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Phosphatidylserine and Curcumin Act Synergistically to Down-Regulate Release of Interleukin-1β from Lipopolysaccharide-Stimulated Cortical Primary Microglial Cells
CNS & Neurological Disorders - Drug Targets Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets A Non-Peptidic MAS1 Agonist AVE0991 Alleviates Hippocampal Synaptic Degeneration in Rats with Chronic Cerebral Hypoperfusion
Current Neurovascular Research The ARRONAX Project
Current Radiopharmaceuticals Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Meet Our Associate Editor
Cardiovascular & Hematological Disorders-Drug Targets